WillItSurvive
Medical technology and health companies · China

111 Inc

111.com.cn ↗

111 Inc runs an online pharmacy and digital health platform in China, trailing far behind two giants.

Little protection left
Assessed 26 July 2026 · Evidence as of 26 July 2026
Not much stands between this business and its pressures.
On the recordSince 26 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Q2 2026 earnings and auditor going-concern language update
The call

111 Inc is a subscale, cash-strained challenger shrinking by choice and by pressure, in a market two much larger rivals already run with live AI tools.

111 Inc runs an online doctor and pharmacy service in China, but it is much smaller than its two main competitors: JD Health (about 6 times larger) and Alibaba Health. Both rivals are adding AI tools to help diagnose patients and answer questions, while 111 Inc has not shown similar advances. The company is also in trouble: its auditor said in April 2026 that the company might not survive, it lost one-third of its revenue in the first quarter of 2026, it has more debt obligations than cash on hand, and it risks being kicked off the stock market. What matters most: whether the company can stop losing money and patients in the next two quarters, whether investors demand their money back all at once, and whether the stock price stays high enough to stay on Nasdaq.

Why
01
AI pressure: JD Health and Alibaba Health AI assistant and triage suites. Both giants already ship AI triage, consultation, and demand tools; 111 has no visible AI product to match. Could AI do the core job? Yes, likely.
02
Bigger players: JD Health International, Alibaba Health. JD Health is roughly six times larger with live AI-assistant products; 111 is shrinking while divesting, not growing against them. Could a giant copy it? Yes, easily.
03
What protects it. A licensed online pharmacy operation and existing prescription volume, offering little protection given its own going-concern doubt.
What would change this call
FY2026 audit opinion on going-concern language for 111 Inc. Shows whether solvency doubt is lifted or reaffirmed by auditors.
111 Inc Q2/Q3 2026 revenue vs prior-year quarter. Shows whether the 33.1% revenue contraction is stabilizing or worsening.
Nasdaq bid-price compliance status for 111 Inc after Feb 2025 reverse split. Shows whether delisting risk is easing or escalating.
Key numbers
  • Q1 2026 revenue fell 33.1% to RMB2.4bn (2026-06-04)
  • FY2025 revenue RMB12.6bn, down 12.8% y/y (2026-04-09)
  • Cash and short-term investments $87.4m (2025-12-31)
Named risks
  • Auditor going-concern doubt raised April 29, 2026. Severity: high
  • RMB1.12bn redeemable investor obligations against only $87.4m cash. Severity: high
  • Revenue contraction accelerating: -12.8% FY2025, -33.1% Q1 2026. Severity: high
  • Recurring Nasdaq minimum bid-price non-compliance risk. Severity: medium
  • Founder super-voting control (92%) limits minority shareholder influence. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
JD Health Internationallosing to111 revenue ~1/6 of JD Health's RMB73.4bn FY2025 revenue (+23% y/y), March 2026
Alibaba Healthlosing toTrades at 39.5x P/E vs JD Health's 26.5x on AI growth expectations, March 2026
MeituancontestingExpanding on-demand drug delivery, intensifying B2C pharmacy competition, 2026
Questions people ask
Is 111 Inc profitable in 2026?
No. 111 Inc posted a non-GAAP net loss of roughly RMB25.7m in Q1 2026 as revenue fell 33.1% y/y to RMB2.4bn ($342.4m), and its auditor raised a going-concern doubt around April 29, 2026, per its Q1 2026 filing.
Who owns 111 Inc?
Co-founders Dr. Gang Yu and Junling Liu control 111 Inc through Class B super-shares carrying 15 votes each, giving them roughly 92% of voting power despite holding only 42.7% of total share capital as of September 2024, per ownership research published September 2025.
Is 111 Inc at risk of Nasdaq delisting?
It has a recent history of risk: 111 fell below Nasdaq's minimum bid-price rule, executed a reverse ADS ratio change in January 2025, and regained compliance in February 2025. Market cap has since stayed around $30-60 million through mid-2026, keeping delisting risk live.
Who is 111 Inc's biggest competitor?
JD Health International is roughly six times larger, with FY2025 revenue of RMB73.4bn versus 111's RMB12.6bn, per March 2026 reporting. Alibaba Health is the other dominant rival; both are shipping AI-assistant suites while 111 lags on visible AI product launches.
Could AI replace 111 Inc's business?
111's demand forecasting, inventory routing, and customer-service workflows are exposed to AI automation. The company claims (unverified, vendor-stated) it is integrating AI into these functions as of June 2026, but it visibly lags larger rivals JD Health and Alibaba Health, which have launched AI-assistant suites.
What is 111 Inc's stock ticker and current size?
111, Inc. trades on Nasdaq as YI. Its market capitalization has been roughly $30-60 million through 2025-2026, down about 45% year-over-year as of June 18, 2026, following revenue declines and going-concern warnings.
Timeline
  • 2026-06-04Q1 2026 net revenue fell to RMB2.4bn ($342.4m), down 33.1% y/y
  • 2026-04-29Auditor raised going-concern doubt in 111 Inc's financial disclosures
  • 2026-04-09FY2025 results: net revenue RMB12.6bn ($1.8bn), down 12.8% y/y
  • 2026-02-28Paid RMB189m ($27m) to 2020-era investors under renegotiated repayment terms
  • 2025-02-11Regained Nasdaq minimum bid-price compliance after reverse ADS ratio change
  • 2025-01Executed 1-for-10 (later 1-for-20) reverse ADS ratio change
  • 2020-121 Pharmacy Technology raised RMB515m at RMB10bn pre-money valuation
  • 2020-081 Pharmacy Technology raised RMB419.82m at $1.2bn pre-money valuation
  • 2018-09111 Inc IPO'd on Nasdaq Global Market
  • 2018-04Company renamed 111, Inc. (founded 2010 as New Peak Group)
Revision history
26 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Winning Health TechnologyCarbon HealthDefinitive Healthcare
More in Medical technology and health companies →
Sources